Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
16
Embed
Journal Pre-proof · Journal Pre-proof Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19 Stephane Picot,
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Since January 2020 Elsevier has created a COVID-19 resource centre with
free information in English and Mandarin on the novel coronavirus COVID-
19. The COVID-19 resource centre is hosted on Elsevier Connect, the
company's public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related
research that is available on the COVID-19 resource centre - including this
research content - immediately available in PubMed Central and other
publicly funded repositories, such as the WHO COVID database with rights
for unrestricted research re-use and analyses in any form or by any means
with acknowledgement of the original source. These permissions are
granted for free by Elsevier for as long as the COVID-19 resource centre
remains active.
Journal Pre-proof
Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19
Stephane Picot, Aileen Marty, Anne-Lise Bienvenu, Lucille H.Blumberg, Jean Dupouy-Camet, Pierre Carnevale, ShigeyukiKano, Malcolm K. Jones, Cláudio Tadeu Daniel-Ribeiro, SantiagoMas-Coma
PII: S2352-7714(20)30062-8
DOI: https://doi.org/10.1016/j.onehlt.2020.100131
Reference: ONEHLT 100131
To appear in: One Health
Please cite this article as: S. Picot, A. Marty, A.-L. Bienvenu, et al., Coalition: Advocacyfor prospective clinical trials to test the post-exposure potential of hydroxychloroquineagainst COVID-19, One Health (2020), https://doi.org/10.1016/j.onehlt.2020.100131
This is a PDF file of an article that has undergone enhancements after acceptance, suchas the addition of a cover page and metadata, and formatting for readability, but it isnot yet the definitive version of record. This version will undergo additional copyediting,typesetting and review before it is published in its final form, but we are providing thisversion to give early visibility of the article. Please note that, during the productionprocess, errors may be discovered which could affect the content, and all legal disclaimersthat apply to the journal pertain.
epidemic. However, its administration should be done under medical control to avo id potential side
effects and to prevent an uncontrolled use leading to supply shortages.
Jour
nal P
re-p
roof
Journal Pre-proof
REFERENCES:
1. Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 20 mars 2020; doi: 10.1093/jac/dkaa114
2. Fanouriakis A, Kostopoulou M, Cheema K, Anders H-J, Aringer M, Bajema I, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 27 mars 2020;
3. Fanouriakis A, Bertsias G, Boumpas DT. Hydroxychloroquine dosing in systemic lupus erythematosus: response to « Letter in response to the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriak is et al » by Costedoat-Chalumeau et al. Ann Rheum Dis. 14 juin 2019;
4. Tett SE, Cutler DJ, Beck C, Day RO. Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis--a prospective, dose ranging study. J Rheumatol. juill 2000;27(7):1656‑ 60.
5. Coatney GR. Pitfalls in a discovery: the chronicle of chloroquine. Am J Trop Med Hyg. mars 1963;12:121‑ 8.
6. Landewé RB, Goei Thè HS, van Rijthoven AW, Breedveld FC, Dijkmans BA. A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum. mai 1994;37(5):637‑ 43.
7. Goldring JP, Nemaorani S. Antimalarial drugs modulate the expression of monocyte receptors. Int J Immunopharmacol. sept 1999;21(9):599‑ 607.
8. Lima TLC, Feitosa R de C, Dos Santos-Silva E, Dos Santos-Silva AM, Siqueira EM da S, Machado PRL, et al. Improving Encapsulation of Hydrophilic Chloroquine Diphosphate into Biodegradable Nanoparticles: A Promising Approach against Herpes Virus Simplex-1 Infection. Pharmaceutics. 3 déc 2018;10(4).
9. Delvecchio R, Higa LM, Pezzuto P, Valadão AL, Garcez PP, Monteiro FL, et al. Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models. Viruses. 29 2016;8(12).
10. Han Y, Pham HT, Xu H, Quan Y, Mesplède T. Antimalarial drugs and their metabolites are potent Zika virus inhibitors. J Med Virol. 2019;91(7):1182‑ 90.
11. Savarino A. Use of chloroquine in viral diseases. Lancet Infect Dis. sept 2011;11(9):653‑ 4.
12. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 22 août 2005;2:69.
Jour
nal P
re-p
roof
Journal Pre-proof
13. Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother. août 2009;53(8):3416‑ 21.
14. Kumar M, Topno RK, Dikhit MR, Bhawana null, Sahoo GC, Madhukar M, et al. Molecular docking studies of chloroquine and its derivatives against P23pro-zbd domain of chikungunya virus: Implication in designing of novel therapeutic strategies. J Cell Biochem. oct 2019;120(10):18298‑ 308.
15. Helal GK, Gad MA, Abd-Ellah MF, Eid MS. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. J Med Virol. 2016;88(12):2170‑ 8.
16. Salata C, Calistri A, Parolin C, Baritussio A, Palù G. Antiviral activity of cationic amphi philic drugs. Expert Rev Anti Infect Ther. 2017;15(5):483‑ 92.
17. Cong Y, Hart BJ, Gross R, Zhou H, Frieman M, Bollinger L, et al. MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. PLoS ONE. 2018;13(3):e0194868.
18. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269‑ 71.
19. Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, et al. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemother. 2006;17(5):275‑ 84.
20. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 9 mars 2020;
21. Braun S, Ferner M, Kronfeld K, Griese M. Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases. Pediatr Pulmonol. avr 2015;50(4):410‑ 9.
22. Lüers J-C, Klußmann JP, Guntinas-Lichius O. [The Covid-19 pandemic and otolaryngology: What it comes down to?]. Laryngorhinootologie. 26 mars 2020;
23. Barnett EM, Perlman S. The olfactory nerve and not the trigeminal nerve is the major site of CNS entry for mouse hepatitis virus, strain JHM. Virology. mai 1993;194(1):185‑ 91.
24. Youngentob SL, Schwob JE, Saha S, Manglapus G, Jubelt B. Functional consequences following infection of the olfactory system by intranasal infusion of the olfactory bulb line variant (OBLV) of mouse hepatitis strain JHM. Chem Senses. oct 2001;26(8):953‑ 63.
25. Netland J, Ferraro D, Pewe L, Olivares H, Gallagher T, Perlman S. Enhancement of murine coronavirus replication by severe acute respiratory syndrome coronavirus protein 6 requires the N-terminal hydrophobic region but not C-terminal sorting motifs. J Virol. oct 2007;81(20):11520‑ 5.
Jour
nal P
re-p
roof
Journal Pre-proof
26. Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy. août 2014;10(8):1359‑ 68.
27. Olafuyi O, Badhan RKS. Dose Optimization of Chloroquine by Pharmacokinetic Modeling During Pregnancy for the Treatment of Zika Virus Infection. J Pharm Sci. janv 2019;108(1):661‑ 73.
28. Collins KP, Jackson KM, Gustafson DL. Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation. J Pharmacol Exp Ther. 2018;365(3):447‑ 59.
29. Chen T-H, Lai T-Y, Wang Y-H, Chiou J-Y, Hung Y-M, Wei JC-C. Hydroxychloroquine was associated with reduced risk of new-onset diabetes mellitus in patients with Sjögren syndrome. QJM. 1 oct 2019;112(10):757‑ 62.
30. Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet. avr 1996;30(4):263‑ 99.
31. Jorge A, Ung C, Young LH, Melles RB, Choi HK. Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. Nat Rev Rheumatol. 2018;14(12):693‑ 703.
32. Osadchy A, Ratnapalan T, Koren G. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. J Rheumatol. déc 2011;38(12):2504‑ 8.
33. Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect. 2017;5(1):e00293.
34. Hu TY, Frieman M, Wolfram J. Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat Nanotechnol. 23 mars 2020;
35. Mallucci L. Effect of chloroquine on lysosomes and on growth of mouse hepatitis virus (MHV-3). Virology. mars 1966;28(3):355‑ 62.
36. Takano T, Katoh Y, Doki T, Hohdatsu T. Effect of chloroquine on feline infectious peritonitis virus infection in vitro and in vivo. Antiviral Res. août 2013;99(2):100‑ 7.
37. Yan Y, Zou Z, Sun Y, Li X, Xu K-F, Wei Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. févr 2013;23(2):300‑ 2.
38. Savarino A, Lucia MB, Rastrelli E, Rutella S, Golotta C, Morra E, et al. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr. 1 mars 2004;35(3):223‑ 32.
39. Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, Turner HL, et al. Pre-fusion structure of a human coronavirus spike protein. Nature. 3 mars 2016;531(7592):118‑ 21.
Jour
nal P
re-p
roof
Journal Pre-proof
40. Ujike M, Taguchi F. Incorporation of spike and membrane glycoproteins into coronavirus virions. Viruses. 3 avr 2015;7(4):1700‑ 25.
41. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. mars 2020;16(3):155‑ 66.
42. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.